Group 1: Fixed Income/Banking - Current oil prices are experiencing a pulse-like increase, with historical patterns showing similarities to the early 2022 Ukraine-Russia conflict, but the current price fluctuations may occur at a faster pace due to market conditions [3][11] - Supply-driven oil price increases are generally not expected to trigger monetary policy tightening, as historical experiences indicate that central banks focus on demand-side adjustments [10][11] - The bond market may experience fluctuations in March, influenced by oil prices affecting market sentiment, but long-term bond risks are considered low due to limited holdings [3][11] Group 2: Overseas/Education Research - The ongoing conflict in the Middle East is a major concern for global markets, with escalating oil prices and declining stock markets indicating investor anxiety [12][15] - The approval of a new commercial nuclear reactor in the U.S. marks a significant milestone for the nuclear energy sector, reflecting renewed policy support for advanced nuclear projects [13] - The commercial aerospace sector is expected to see revenue growth driven by government contracts and commercial agreements, despite high capital expenditures and operational losses [14][15] Group 3: Machinery/Construction - The 2026 National People's Congress emphasizes the importance of effective investment, with a focus on major infrastructure projects and the "Six Networks" initiative, which includes water and electricity networks [16][19] - The fiscal policy remains proactive, with record-high government spending and special bond issuance aimed at supporting infrastructure investments [17][19] - The construction sector is expected to benefit from stable infrastructure demand, particularly in energy security and clean energy projects [19] Group 4: Pharmaceuticals - Hutchison China MediTech reported a total revenue of $549 million for 2025, a decrease of 12.96%, while net profit surged by 1111.03% to $457 million [21][22] - The company’s oncology/immunology business generated $286 million, with significant growth in international sales, particularly for its drug, fruquintinib [22][23] - The ATTC platform is progressing into clinical validation, with multiple candidates entering trials, indicating a robust pipeline for future growth [23][24] Group 5: Home Appliances - Bosideng is expected to achieve steady revenue growth, with a projected mid-single-digit increase for the fiscal year, despite a warm winter affecting sales [26][27] - The main brand, down jackets, is anticipated to maintain growth, supported by high-profile designer collaborations [26][27] - The company is focusing on improving operational efficiency and management capabilities across its various business segments [27][28] Group 6: North Exchange - North Mining Testing is positioned as a leader in the non-ferrous metal testing sector, benefiting from rising metal prices and the domestic demand for quality control [30][31] - The testing services market is projected to reach ¥487.6 billion by 2024, with a significant shift towards larger, more concentrated firms [30][31] - The company is expanding its business model to include high-end instrument development, enhancing its competitive edge in the market [31][32]